Quantitative Estimation of Clinical Intrasubject Variability of a Pharmacokinetic Parameter
- 5 June 2026
- journal article
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (4)
Abstract
The virtual bioequivalence (VBE) approach, which employs physiologically based pharmacokinetic (PBPK) modeling in lieu of clinical bioequivalence (BE) studies, provides a valuable alternative for the pharmaceutical industry. The VBE has the potential to substantially reduce both the time and costs associated with traditional clinical BE studies. Furthermore, this approach supports ethical principles by eliminating the need to expose healthy volunteers to investigational compounds without medical benefit. Intrasubject variability (intrasubject coefficient of variation, ICV) is a main factor for balanced cross-over design BE studies in calculating the confidence intervals for the geometric mean ratio of AUC and Cmax, which determines if bioequivalence criteria are met. Thus, it is essential to employ realistic and accurate ICV values for BE assessment through PBPK modeling. Published literature indicates that the drug properties that affect oral bioavailability exhibit a good correlation with ICV. The aim of this research is to expand drug databases to reevaluate the correlation between drug properties and clinically observed ICV for Cmax (ICV_Cmax). The results demonstrated that the dose number (dose to solubility ratio), permeability and elimination half-life are three main factors influencing ICV_Cmax. Permeability becomes a dominating factor when the value is relatively low (Papp < 0.8 × 10-6 cm/sec). In addition, PBPK modeling tools, Gastroplus and Simcyp were evaluated for their ability to predict ICV_Cmax based on drug properties and their built-in physiological variations. Both simulation tools estimated intersubject variability and ICV_Cmax similarly and underestimated ICV_Cmax compared with clinically observed ICV_Cmax.Keywords
This publication has 29 references indexed in Scilit:
- From hypothesis to forecasting: The impact of within-subject variability of gastro-intestinal physiology in relation to likelihood of sex-dependent outcome of bioequivalenceEuropean Journal of Pharmaceutical Sciences, 2025
- Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage FormClinical Pharmacology & Therapeutics, 2024
- Predicting bioequivalence and developing dissolution bioequivalence safe space in vitro for warfarin using a Physiologically-Based pharmacokinetic absorption modelEuropean Journal of Pharmaceutics and Biopharmaceutics, 2023
- Regulatory utility of physiologically‐based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary reportCPT: Pharmacometrics & Systems Pharmacology, 2023
- Quantitative estimation of intra-subject variability in bioequivalence studies of generic solid oral dosage forms by multiple regression analysisJournal of Drug Delivery Science and Technology, 2021
- Application of physiologically based biopharmaceutics modeling to understand the impact of dissolution differences on in vivo performance of immediate release products: The case of bisoprololCPT: Pharmacometrics & Systems Pharmacology, 2021
- Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of In Vivo Clinical Studies: Current Status, Challenges, and OpportunitiesMolecular Pharmaceutics, 2020
- Mechanistic investigation of the negative food effect of modified release zolpidemEuropean Journal of Pharmaceutical Sciences, 2017
- Tramadol Hydrochloride2013
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987